Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
HK Stock Market Move | Summer box office surpasses 3.5 billion yuan, DAMAI ENT(01060) surges over 7%, MAOYAN ENT(01896) surges over 5%.
A-share market closing review | A-shares plunged on low trading volume, with the Shanghai Composite Index falling by 1.85%! Four major reasons exposed, pharmaceutical sector active against the market.
HK Stock Market Move | UNITED LAB (03933) rises over 3%. Federal Biotechnology has received milestone payment related to the exclusive licensing agreement for Novartis UB251.
HK Stock Market Move | Summer box office surpasses 3.5 billion yuan, DAMAI ENT(01060) surges over 7%, MAOYAN ENT(01896) surges over 5%.
A-share market closing review | A-shares plunged on low trading volume, with the Shanghai Composite Index falling by 1.85%! Four major reasons exposed, pharmaceutical sector active against the market.
HK Stock Market Move | UNITED LAB (03933) rises over 3%. Federal Biotechnology has received milestone payment related to the exclusive licensing agreement for Novartis UB251.
RECOMMEND
